HighGravityDataEli Lilly — Oct 30, 2024 release
Fiscal 2024 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000059478-24-000242
Showing in the filing
Non-GAAP EPS
“$13.02 to $13.52”
Period
FY2024
Measure
Company-defined measure
Source
Prose
All guidance in this release · 12
Non-GAAP EPS for FY2024
“$13.02 to $13.52”
Revenue for FY2024
“$45.4 billion and $46.0 billion”
Acquired IPR&D charges included in for FY2024
“$3.09 billion, or $3.33 on a per share basis”
Asset impairment, restructuring and other sp… for FY2024
“$517 million”
Tax rate for FY2024
“approximately 17%”
Earnings per share, non-GAAP basis for FY2024
“$13.02 to $13.52”
Earnings per share, reported basis for FY2024
“$12.05 to $12.55”
Reported EPS for FY2024
“$12.05 to $12.55”
(Gross Margin - OPEX)/Revenue (reported) for FY2024
“36% to 38%”
(Gross Margin - OPEX)/Revenue (non-GAAP) for FY2024
“37% to 39%”
Other income (expense) (reported) for FY2024
“($425) to ($325) million”
Other income (expense) (non-GAAP) for FY2024
“($400) to ($300) million”
Exhibit 99.1 · the passage around this item
… earlier in the release
• Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.08 of acquired IPR&D charges. • 2024 revenue guidance range updated to $45.4 to $46.0 billion. 2024 reported EPS guidance updated to the range of $12.05 to $12.55, and non-GAAP EPS guidance updated to the range of $13.02 to $13.52, both driven by the acquired IPR&D charges incurred in Q3. • Approvals included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease. • Positive Phase 3 data included the 176-week study of tirzepatide showing 94% reduction in the risk of developing type 2 diabetes in adults with pre-diabetes, and obesity or overweight, and the six-month TRAILBLAZER-ALZ 6 trial showing that modified titration achieved similar levels of amyloid plaque removal while also reducing the incidence of ARIA-E to 14%, compared with 24% in the standard dosing regimen. INDIANAPOLIS, Oct. 30, 2024 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the third quarter of 2024. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding divestiture activity in the same period last year," said David A. Ricks, Lilly chair and CEO. "While the growth of Mounjaro and Zepbound is impressive, we are equally proud of the 17% growth in non-incretin revenue, which includes our oncology, immunology and neuroscience portfolios, compared with Q3 2023 on the same basis. The new product appro
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.